Denali Therapeutics Inc's Comment on Sales, Marketing and Customers
The company initially serves patients with rare indications and plans to expand to larger indications over time. It targets common neurodegenerative diseases, including Alzheimer's disease and Parkinson's disease, which affect over 40 million individuals worldwide. Its specific programs include DNL628 (OTV:MAPT) for Alzheimer's disease targeting tau, and DNL921 (ATV:Abeta) targeting amyloid plaques. The company also develops therapeutics for lysosomal storage diseases and oncology, including a bispecific ATV:HER2 antibody for HER2-positive peripheral tumors and brain metastases. It has a collaboration with Biogen Inc. subsidiaries Biogen MA Inc. and Biogen International GmbH for the development and commercialization of BIIB122/DNL151, a LRRK2 inhibitor for Parkinson's disease. Biogen is conducting the global Phase 2b LUMA study with 650 participants, while the company is conducting the Phase 2a BEACON study in LRRK2-associated Parkinson's disease. The company opened a clinical biomanufacturing facility in March 2025. Customers and markets include Biogen Inc., Biogen International GmbH, and Biogen MA Inc.
Denali Therapeutics Inc. has recently announced a successful meeting with the U.S. Food and Drug Administration (FDA) concerning its investigational therapeutic, Tividenofusp Alfa (DNL310), aimed at treating Mucopolysaccharidosis Type II (MPS II), commonly known as Hunter Syndrome. The meeting was a significant milestone for the company, as it signals a forthcoming application for accelerated approval, a pathway that could expedite access to this potentially transformative therapy for patients suffering from this rare genetic disorder.Tividenofusp Alfa has been designed to address the underlying causes of MPS II by targeting the enzyme deficiency that leads to the gradual accumulation of glycosaminoglycans (...
In the venerable realm of biopharmaceutical innovation, the illustrious Denali Therapeutics Inc., headquartered in the charming enclave of South San Francisco, has recently revealed a monumental stride in medical science, one that reverberates with profound implications for the treatment of neurodegenerative and lysosomal storage maladies. The company, whose endeavours are predominantly focused upon the sanctified challenge of traversing the formidable blood-brain barrier (BBB), has announced an enlightening publication in the esteemed journal Science Translational Medicine . This august document highlights the promising capabilities of the Oligonucleotide Transport Vehicle (OTV) platform to engender broad ...
:Denali Therapeutics, a renowned biopharmaceutical company, recently announced its expansion and promising new data regarding its work on enzyme replacement therapies (ERTs) engineered to traverse the blood-brain barrier (BBB) for treating neurodegenerative and lysosomal storage diseases. This report will specifically focus on the exciting progress the company has made in the development of ERTs for the treatment of mucopolysaccharidoses (MPS) disorders.Mucopolysaccharidoses represent a group of severe metabolic disorders characterized by the accumulation of glycosaminoglycans due to enzyme deficiencies. Two specific types of MPS, namely MPS II or Hunter syndrome and MPS IIIA or Sanfilippo syndrome type A, h...
Denali Therapeutics Inc’s Comment on Sales, Marketing and Customers
The company initially serves patients with rare indications and plans to expand to larger indications over time. It targets common neurodegenerative diseases, including Alzheimer's disease and Parkinson's disease, which affect over 40 million individuals worldwide. Its specific programs include DNL628 (OTV:MAPT) for Alzheimer's disease targeting tau, and DNL921 (ATV:Abeta) targeting amyloid plaques. The company also develops therapeutics for lysosomal storage diseases and oncology, including a bispecific ATV:HER2 antibody for HER2-positive peripheral tumors and brain metastases. It has a collaboration with Biogen Inc. subsidiaries Biogen MA Inc. and Biogen International GmbH for the development and commercialization of BIIB122/DNL151, a LRRK2 inhibitor for Parkinson's disease. Biogen is conducting the global Phase 2b LUMA study with 650 participants, while the company is conducting the Phase 2a BEACON study in LRRK2-associated Parkinson's disease. The company opened a clinical biomanufacturing facility in March 2025. Customers and markets include Biogen Inc., Biogen International GmbH, and Biogen MA Inc.
Sources:
Denali Therapeutics Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Denali Therapeutics Inc’s corporate clients.
For your research, we’ve provided 9 tables on Denali Therapeutics Inc corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
2774.69 %